85 related articles for article (PubMed ID: 28539278)
1. [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells].
Peng YJ; Wu QY; Liu HY; Zhao J; Wei HF
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):581-587. PubMed ID: 28539278
[TBL] [Abstract][Full Text] [Related]
2. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells.
Eugene-Norbert M; Cuffel A; Riou G; Jean L; Blondel C; Dehayes J; Bisson A; Giverne C; Brotin E; Denoyelle C; Poulain L; Boyer O; Martinet J; Latouche JB
J Immunol Methods; 2024 Feb; 525():113603. PubMed ID: 38147898
[TBL] [Abstract][Full Text] [Related]
3. Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19.
Fioretti S; Matson CA; Rosenberg KM; Singh NJ
Cancer Immunol Immunother; 2023 Jan; 72(1):257-264. PubMed ID: 35753001
[TBL] [Abstract][Full Text] [Related]
4. [Construction and Optimization of CD19 Chimeric Antigen Receptor T Cells Derived from C57BL/6J Mice].
Ren CX; Zhao L; Chen XX; Tian Y; Zhao K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):595-602. PubMed ID: 38660872
[TBL] [Abstract][Full Text] [Related]
5. Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development.
Goldberg L; Haas ER; Urak R; Vyas V; Pathak KV; Garcia-Mansfield K; Pirrotte P; Singhal J; Figarola JL; Aldoss I; Forman SJ; Wang X
Cancer Res; 2024 Apr; 84(7):1048-1064. PubMed ID: 38315779
[TBL] [Abstract][Full Text] [Related]
6. [Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration].
Chen ML; Peng N; Liu XY; Zhang T; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):217-223. PubMed ID: 33910307
[No Abstract] [Full Text] [Related]
7. Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy.
Hou F; Guo Z; Ho MT; Hui Y; Zhao CX
ACS Nano; 2024 Mar; 18(12):8571-8599. PubMed ID: 38483840
[TBL] [Abstract][Full Text] [Related]
8. Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.
Chen JY; Agrawal S; Yi HP; Vallejo D; Agrawal A; Lee AP
Adv Healthc Mater; 2023 May; 12(12):e2203163. PubMed ID: 36645182
[TBL] [Abstract][Full Text] [Related]
9. DNA origami-based artificial antigen-presenting cells for adoptive T cell therapy.
Sun Y; Sun J; Xiao M; Lai W; Li L; Fan C; Pei H
Sci Adv; 2022 Dec; 8(48):eadd1106. PubMed ID: 36459554
[TBL] [Abstract][Full Text] [Related]
10. Artificial Targets: a versatile cell-free platform to characterize CAR T cell function
Wang X; Tokarew NJA; Borgelt N; Siemer R; Melo CC; Langer C; Kasampalidis I; Ogusuku IEY; Cathomen T; Gessner I; Dose C; Fauerbach JA; Richter A; Evaristo C
Front Immunol; 2024; 15():1254162. PubMed ID: 38433827
[TBL] [Abstract][Full Text] [Related]
11. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.
Sunshine JC; Perica K; Schneck JP; Green JJ
Biomaterials; 2014 Jan; 35(1):269-277. PubMed ID: 24099710
[TBL] [Abstract][Full Text] [Related]
12. Getting CD19 Into Shape: Expression of Natively Folded "Difficult-to- Express" CD19 for Staining and Stimulation of CAR-T Cells.
Lobner E; Wachernig A; Gudipati V; Mayrhofer P; Salzer B; Lehner M; Huppa JB; Kunert R
Front Bioeng Biotechnol; 2020; 8():49. PubMed ID: 32117929
[TBL] [Abstract][Full Text] [Related]
13. The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma.
Dong YH; Ding YM; Guo W; Huang JW; Yang Z; Zhang Y; Chen XH
Onco Targets Ther; 2018; 11():7053-7059. PubMed ID: 30410362
[TBL] [Abstract][Full Text] [Related]
14. Nanoengineering approaches to the design of artificial antigen-presenting cells.
Sunshine JC; Green JJ
Nanomedicine (Lond); 2013 Jul; 8(7):1173-89. PubMed ID: 23837856
[TBL] [Abstract][Full Text] [Related]
15. Author Correction: Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains.
Gordon KS; Kyung T; Perez CR; Holec PV; Ramos A; Zhang AQ; Agarwal Y; Liu Y; Koch CE; Starchenko A; Joughin BA; Lauffenburger DA; Irvine DJ; Hemann MT; Birnbaum ME
Nat Biomed Eng; 2023 Apr; 7(4):599-602. PubMed ID: 36737667
[No Abstract] [Full Text] [Related]
16. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.
Schmueck-Henneresse M; Omer B; Shum T; Tashiro H; Mamonkin M; Lapteva N; Sharma S; Rollins L; Dotti G; Reinke P; Volk HD; Rooney CM
J Immunol; 2017 Jul; 199(1):348-362. PubMed ID: 28550199
[TBL] [Abstract][Full Text] [Related]
17. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
Perera LP; Zhang M; Nakagawa M; Petrus MN; Maeda M; Kadin ME; Waldmann TA; Perera PY
Am J Hematol; 2017 Sep; 92(9):892-901. PubMed ID: 28543380
[TBL] [Abstract][Full Text] [Related]
19. Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression.
Guha P; Cunetta M; Somasundar P; Espat NJ; Junghans RP; Katz SC
J Leukoc Biol; 2017 Aug; 102(2):201-208. PubMed ID: 28546503
[TBL] [Abstract][Full Text] [Related]
20. Adoptive T cell therapy: An overview of obstacles and opportunities.
Baruch EN; Berg AL; Besser MJ; Schachter J; Markel G
Cancer; 2017 Jun; 123(S11):2154-2162. PubMed ID: 28543698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
